Alcohol and Alcoholism
January 17, 2024
Ewen Kervadec, Baptiste Fauvel, Lana Strika-Bruneau et al.
15 citations
Alcohol use can be significantly associated with negative social, professional, and health outcomes. Even more so, alcohol use disorder (AUD) is a critical public health issue and major avoidable risk factor. This study aimed to examine the effect of a naturalistic psychedelic experience on alcohol use and related measures. A retrospective online survey was conducted on 160 individuals who...
Frontiers in Neuroscience
2024
Demi Govender, Leila Moloko, Maria Papathanasopoulos et al.
10 citations
Ibogaine is a psychedelic alkaloid being investigated as a possible treatment for opioid use disorder. Ibogaine has a multi-receptor profile with affinities for mu and kappa opioid as well as NMDA receptors amongst others. Due to the sparsity of research into ibogaine's effects on white matter integrity and given the growing evidence that opioid use disorder is characterized by white matter...
Frontiers in Pharmacology
2024
Carles Colom-Rocha, Cristian Bis-Humbert, M Julia García-Fuster
3 citations
Few studies have previously evaluated the long-term impact of initiating the combined use of alcohol and cocaine early-in-life during adolescence. Our preclinical study characterized changes in affective-like behavior and/or voluntary ethanol consumption emerging later on in adulthood induced by a prior adolescent drug exposure, as well as tested therapeutical interventions (i.e., cannabidiol...
Frontiers in Pharmacology
2024
Luan Oliveira Ferreira, Esther Padilha da Silveira, Clarissa A Paz et al.
Substance abuse is a major public health problem. In recent years, ketamine, which is a parenteral anesthetic, has been consumed increasingly as an illicit drug together with alcohol, although little is known of how this association alters brain activity. The present study investigated the influence of progressive doses of ketamine, associated with alcohol, on electrophysiological activity. For...
Journal of Addictive Diseases
2024
Alexandra Arenson, Cynthia I Campbell, Ilan Remler
8 citations
The opioid epidemic and limited access to treatment for opioid withdrawal (OW) and opioid use disorder (OUD) has led individuals to seek alternative treatments. This narrative review aims to educate clinicians on the mechanisms of action, toxicity, and applications of psychoactive plant-based substances patients may be using to self-treat OUD and OW. We specifically discuss ayahuasca, ibogaine,...
Pharmaceuticals
December 21, 2023
Katarina Savić Vujović, Ana Jotić, Branislava Medić et al.
32 citations
Ketamine as an old-new drug has a variety of clinical implications. In the last 30 years, ketamine has become popular for acute use in humans. Ketamine in standard doses is principally utilized for the induction and maintenance of surgical procedures. Besides its use in anesthesia and analgesia, recent studies have shown that ketamine has found a place in the treatment of asthma, epilepsy,...
Theoretical and Natural Science
December 20, 2023
Jingxuan Chen
Psilocybin is a naturally occurring psychoactive compound, which has been used for ages in traditional settings for religious and therapeutic use. Recent studies have renewed interest in psilocybin for its potential therapeutic benefits in treating depression and anxiety. The pharmacodynamics of psilocybin are complex, involving its rapid conversion to psilocin and its activity on various...
Translational Psychiatry
December 14, 2023
Ivan Skorodumov, Rainer Spanagel, Jonathan R Reinwald et al.
25 citations
Abstract Alcohol Use Disorder (AUD) adversely affects the lives of millions of people, but still lacks effective treatment options. Recent advancements in psychedelic research suggest psilocybin to be potentially efficacious for AUD. However, major knowledge gaps remain regarding (1) psilocybin’s general mode of action and (2) AUD-specific alterations of responsivity to psilocybin treatment in...
Drug and Alcohol Dependence
December 1, 2023
Caryssa R Drinkuth, Michael J Lehane, Gregory C Sartor
9 citations
Despite the thousands of lives lost during the ongoing opioid crisis, a scarcity of new and effective clinical treatments for opioid use disorder (OUD) remains. To address this unmet need, some researchers have turned to dissociative and psychedelic drugs to treat multiple psychiatric conditions. In particular, low doses of ketamine have been shown to attenuate opioid withdrawal and drug use in...
Journal of Psychopharmacology
December 1, 2023
Genís Ona, Ingrid Reverte, Giordano N. Rossi et al.
20 citations
There is a growing interest in studying ibogaine (IBO) as a potential treatment for substance use disorders (SUDs). However, its clinical use has been hindered for mainly two reasons: First, the lack of randomized, controlled studies informing about its safety and efficacy. And second, IBO's mechanisms of action remain obscure. It has been challenging to elucidate a predominant mechanism of...